Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Diagnosing Infections with Multi-Drug Resistant Microorganisms using AI-powered Genomic Antibiotic Susceptibility Prediction from Long-Read Sequencing Data

Project description

Rapid diagnostics to combat antimicrobial resistance

Antimicrobial resistance (AMR) is a global health crisis, with a projected 10 million annual deaths by 2050. The lack of fast, accessible, and precise diagnostics hampers efforts to detect infections and guide antibiotic therapy effectively. Current methods often take too long or lack necessary data, while access is limited due to infrastructure and personnel needs. To tackle this, the EU-funded DRAIGON project is developing a groundbreaking diagnostic tool. Using accelerated whole genome sequencing combined with AI, the project aims to detect any pathogen-antibiotic combination rapidly. The system will focus on bloodstream and prosthetic joint infections, offering a powerful early warning tool for preventing outbreaks and cross-border pathogen spread, particularly in regions with high AMR burdens.

Objective

The silent pandemic of antimicrobial resistance (AMR) is a growing global health crisis with a projected annual mortality rate of 10 million by 2050. Addressing this crisis critically depends on fast, accessible and precise diagnostics to improve detection and prevention of infection and guide antibiotic therapy. Current diagnostics often have insufficient turnaround time or data for timely detection and prevention of outbreaks or precision antibiotic therapy guidance, and accessibility is often limited due to the required infrastructure and expert personnel. To overcome these shortcomings, and address AMR, we are developing a diagnostic based on accelerated whole genome sequencing linked with AI-assisted data analysis. This project termed “DRAIGON” includes a consortium of internationally recognized experts in sequencing platform and assay development, bioinformatics and machine learning, clinical microbiology, infection prevention and control, antibiotic therapy and stewardship, and health economics to jointly develop our in vitro diagnostic solution to target virtually any pathogen-antibiotic combination. We propose to validate and demonstrate the clinical utility of DRAIGON focusing on bloodstream and prosthetic joint infections at five independent sites, including one located in a medium income country representative of areas with a high AMR burden and reduced access to laboratory infrastructure. The diagnostic will be easy to implement and functions as an early detection system to prevent the cross-border spread of pathogens. In rapidly and accurately providing pathogen ID and type, a comprehensive antibiogram, and outbreak cluster information directly from genome data and in a single assay, this innovative high-resolution diagnostic aims to reinforce the global fight against AMR infections and enable the antibiotic stewardship goals of “right antibiotic, at the right dose, for the right patient, and at the right time”.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-IA - HORIZON Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-HLTH-2023-TOOL-05

See all projects funded under this call

Coordinator

EUROPEAN VACCINE INITIATIVE EV
Net EU contribution
€ 842 916,25
Address
IM NEUENHEIMER FELD 515
69120 Heidelberg
Germany
Region
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Activity type
Research Organisations
Links
Total cost
€ 842 916,25

Participants (7)

Partners (2)